Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma
NCT03370718Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in adrenocortical carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT03370718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370718.